Puja K. Mehta
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Puja K. Mehta has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Cathleen Noel Bairey Merz
Barbra Streisand Women’s Heart Center, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA
5 shared publications Shilpa Agrawal
David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
2 shared publicationsAfsaneh Haftbaradaran
The Barbra Streisand Women’s Heart Center, Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California
1 shared publicationC. Noel Bairey Merz
Cedars-Sinai Heart Institute, Barbra Streisand Women's Heart Center, 127 S. San Vicente Blvd, A3212, Los Angeles, CA, 90048, USA
1 shared publication- Chrisandra Shufelt
Division of General Internal Medicine, Mayo Clinic, Jacksonville, FL
1 shared publication Esha Sachdev
Barbra Streisand Women's Heart Center, Cedars-Sinai Heart Institute, Los Angeles, California, US
1 shared publication
Latest Publications
- 1 January 2016
- Published by Elsevier in Heart Failure Clinics
- Vol. 12 (1) , 141-156
Cardiac Syndrome X
- 1 January 2016
- Published by Elsevier in Heart Failure Clinics
- Vol. 12 (1) , 141-156
Cardiac Syndrome X
- 21 October 2015
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 17 (12) , 1-14
Breast Cancer Survivorship and Cardiovascular Disease: Emerging Approaches in Cardio-Oncology
Opinion statement Cardiovascular disease (CVD) and breast cancer cause substantial morbidity and mortality in women and are major public health concerns in the USA. While aggressive screening and targeted, advanced treatment for breast cancer have had a measurable impact on breast cancer survival, treatment is not without significant cardiotoxic effects. Anthracycline-based chemotherapy can lead to left ventricular dysfunction and failure, as well as a decline in exercise tolerance and cardio-pulmonary reserve despite preserved ejection fraction. Trastuzumab, a newer monoclonal antibody targeting the Her2 receptor used in the treatment of Her2+ cancer, is also linked to left ventricular dysfunction, although the long-term cardiac effects are presently unclear. Radiation treatment particularly for left-sided breast cancer has been associated with increased rates of ischemic heart disease. As women have increasing survival and cure rates from early breast cancer, long-term consequences on the heart that are secondary to therapy are a major concern. These need to be identified, treated, and avoided when possible. Further research and clear surveillance guidelines are needed to aid the practicing clinician in CVD prevention in breast cancer survivors.
- 21 October 2015
- Published by Springer Nature in Current Treatment Options in Cardiovascular Medicine
- Vol. 17 (12) , 1-14
Breast Cancer Survivorship and Cardiovascular Disease: Emerging Approaches in Cardio-Oncology
Opinion statement Cardiovascular disease (CVD) and breast cancer cause substantial morbidity and mortality in women and are major public health concerns in the USA. While aggressive screening and targeted, advanced treatment for breast cancer have had a measurable impact on breast cancer survival, treatment is not without significant cardiotoxic effects. Anthracycline-based chemotherapy can lead to left ventricular dysfunction and failure, as well as a decline in exercise tolerance and cardio-pulmonary reserve despite preserved ejection fraction. Trastuzumab, a newer monoclonal antibody targeting the Her2 receptor used in the treatment of Her2+ cancer, is also linked to left ventricular dysfunction, although the long-term cardiac effects are presently unclear. Radiation treatment particularly for left-sided breast cancer has been associated with increased rates of ischemic heart disease. As women have increasing survival and cure rates from early breast cancer, long-term consequences on the heart that are secondary to therapy are a major concern. These need to be identified, treated, and avoided when possible. Further research and clear surveillance guidelines are needed to aid the practicing clinician in CVD prevention in breast cancer survivors.
- 13 June 2015
- Published by Elsevier in Trends in Cardiovascular Medicine
- Vol. 26 (1) , 89-91
Stroke in women: Where are we in 2015?
- 13 June 2015
- Published by Elsevier in Trends in Cardiovascular Medicine
- Vol. 26 (1) , 89-91
Stroke in women: Where are we in 2015?
- 1 February 2015
- Published by Elsevier in Trends in Cardiovascular Medicine
- Vol. 25 (2) , 140-151
Ischemic heart disease in women: A focus on risk factors
- 1 February 2015
- Published by Elsevier in Trends in Cardiovascular Medicine
- Vol. 25 (2) , 140-151
Ischemic heart disease in women: A focus on risk factors
- 1 January 2015
- Published by Radcliffe Medical Media Ltd in European Cardiology Review
- Vol. 10 (1) , 25-30
Takotsubo Cardiomyopathy
Takotsubo cardiomyopathy (TTC) is an acute, stress-induced cardiomyopathy with an increased prevalence in post-menopausal women. The syndrome is most frequently precipitated by an acute emotional or physical stressor and mimics acute myocardial infarction with symptoms, electrocardiogram (ECG) changes and cardiac troponin elevation that are indistinguishable from those caused by plaque rupture or coronary thrombosis. Diagnosis of TTC is made when coronary angiography reveals no obstructive coronary artery disease and the left ventricle demonstrates apical ballooning and basal hypercontractility. Other ventricular patterns have also been described. An abnormal myocardial response to the catecholamine surge from an emotional or a physical stressor is implicated in the pathophysiology, but the reasons for the high prevalence of TTC presentations in post-menopausal women are unknown. Several mechanisms including multi-vessel coronary vasospasm, endothelial and coronary microvascular dysfunction and direct catecholamine toxicity have been proposed. No specific guidelines for treatment of TTC have been established, but treatment is based on the American Heart Association/ American College of Cardiology guidelines for acute coronary syndrome/acute myocardial infarction and heart failure guidelines. In this review article, we discuss the characteristic clinical presentation of TTC and the commonly proposed mechanisms.
- 1 January 2015
- Published by Radcliffe Medical Media Ltd in European Cardiology Review
- Vol. 10 (1) , 25-30
Takotsubo Cardiomyopathy
Takotsubo cardiomyopathy (TTC) is an acute, stress-induced cardiomyopathy with an increased prevalence in post-menopausal women. The syndrome is most frequently precipitated by an acute emotional or physical stressor and mimics acute myocardial infarction with symptoms, electrocardiogram (ECG) changes and cardiac troponin elevation that are indistinguishable from those caused by plaque rupture or coronary thrombosis. Diagnosis of TTC is made when coronary angiography reveals no obstructive coronary artery disease and the left ventricle demonstrates apical ballooning and basal hypercontractility. Other ventricular patterns have also been described. An abnormal myocardial response to the catecholamine surge from an emotional or a physical stressor is implicated in the pathophysiology, but the reasons for the high prevalence of TTC presentations in post-menopausal women are unknown. Several mechanisms including multi-vessel coronary vasospasm, endothelial and coronary microvascular dysfunction and direct catecholamine toxicity have been proposed. No specific guidelines for treatment of TTC have been established, but treatment is based on the American Heart Association/ American College of Cardiology guidelines for acute coronary syndrome/acute myocardial infarction and heart failure guidelines. In this review article, we discuss the characteristic clinical presentation of TTC and the commonly proposed mechanisms.
- Open Access
- 1 January 2014
- Published by Elmer Press, Inc. in Journal of Medical Cases
- Vol. 5 (1)
Ranolazine as Treatment of Microvascular Coronary Dysfunction in a Woman With Signs and Symptoms of Ischemia but No Obstructive Coronary Artery Disease
- 1 January 2014
- Published by Elmer Press, Inc. in Journal of Medical Cases
- Vol. 5 (1)
Open AccessRanolazine as Treatment of Microvascular Coronary Dysfunction in a Woman With Signs and Symptoms of Ischemia but No Obstructive Coronary Artery Disease